Jun Liu

Jun Liu

Auto-generated profile, based on publicly available information

Jun Liu

Pathology Division, USAMRIID, Fort Detrick, Frederick, MD 21702, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 October 2020 in JCI Insight
Verified
Journal Article
Open access
PDF file
JGJoseph Golden
Joseph Golden
CCCurtis R. Cline
Curtis R. Cline
XZXiankun Zeng
Xiankun Zeng
AGAura R. Garrison
Aura R. Garrison
BCBrian Carey
Brian Carey
JHJay Hooper
Jay Hooper
The emergence of SARS-CoV-2 has created an international health crisis, and small animal models mirroring SARS-CoV-2 human disease are essential for medical countermeasure (MCM) development. Mice are refractory to SARS-CoV-2 infection owing to low-affinity binding to the murine angiotensin-converting enzyme 2 (ACE2) protein. Here, we evaluated the pathogenesis of SARS-CoV-2 in male and female mice expressing the human ACE2 gene under the control of the keratin 18 promoter (K18). In contrast to nontransgenic mice, intranasal exposure of K18-hACE2 animals to 2 different doses of SARS-CoV-2 resulted in acute disease, including weight loss, lung injury, brain infection, and lethality. Vasculitis was the most prominent finding in the lungs of infected mice. Transcriptomic analysis from lungs of infected animals showed increases in transcripts involved in lung injury and inflammatory cytokines. In the low-dose challenge groups, there was a survival advantage in the female mice, with 60% surviving infection, whereas all male mice succumbed to disease. Male mice that succumbed to disease had higher levels of inflammatory transcripts compared with female mice. To our knowledge, this is the first highly lethal murine infection model for SARS-CoV-2 and should be valuable for the study of SARS-CoV-2 pathogenesis and for the assessment of MCMs.

18 June 2020 in JCI Insight
Verified
Journal Article
Closed access
PDF file
JLJun Liu
Jun Liu
ABApril M. Babka
April M. Babka
BKBrian Kearney
Brian Kearney
SRSheli R. Radoshitzky
Sheli R. Radoshitzky
Jens H. KuhnJens H. Kuhn
Jens H. Kuhn
XZXiankun Zeng
Xiankun Zeng
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of human coronavirus disease 2019 (COVID-19), emerged in Wuhan, China, in December 2019. The virus rapidly spread globally, resulting in a public health crisis including almost 5 million cases and 323,256 deaths as of May 21, 2020. Here, we describe the identification and evaluation of commercially available reagents and assays for the molecular detection of SARS-CoV-2 in infected FFPE cell pellets. We identified a suitable rabbit polyclonal anti–SARS-CoV spike protein antibody and a mouse monoclonal anti–SARS-CoV nucleocapsid protein (NP) antibody for cross-detection of the respective SARS-CoV-2 proteins by IHC and immunofluorescence assay (IFA). Next, we established RNAscope in situ hybridization (ISH) to detect SARS-CoV-2 RNA. Furthermore, we established a multiplex FISH (mFISH) to detect positive-sense SARS-CoV-2 RNA and negative-sense SARS-CoV-2 RNA (a replicative intermediate indicating viral replication). Finally, we developed a dual staining assay using IHC and ISH to detect SARS-CoV-2 antigen and RNA in the same FFPE section. It is hoped that these reagents and assays will accelerate COVID-19 pathogenesis studies in humans and in COVID-19 animal models.

1 February 2018 in Blood Cells, Molecules, and Diseases
Verified
Journal Article
Closed access
VMVagishwari Murugesan
Vagishwari Murugesan
JLJun Liu
Jun Liu
RYRuhua Yang
Ruhua Yang
HLHaiquin Lin
Haiquin Lin
ALAndrew Lischuk
Andrew Lischuk
PMPramod Mistry
Pramod Mistry

9 February 2022 in Science Translational Medicine
Verified
Journal Article
Closed access
JLJun Liu
Jun Liu
JTJohn C. Trefry
John C. Trefry
ABApril M. Babka
April M. Babka
CSChristopher W. Schellhase
Christopher W. Schellhase
KCKayla M. Coffin
Kayla M. Coffin
XZXiankun Zeng
Xiankun Zeng
Effective therapeutics have been developed against acute Ebola virus disease (EVD) in both humans and experimentally infected nonhuman primates. However, the risk of viral persistence and associated disease recrudescence in survivors receiving these therapeutics remains unclear. In contrast to rhesus macaques that survived Ebola virus (EBOV) exposure in the absence of treatment, we discovered that EBOV, despite being cleared from all other organs, persisted in the brain ventricular system of rhesus macaque survivors that had received monoclonal antibody (mAb) treatment. In mAb-treated macaque survivors, EBOV persisted in macrophages infiltrating the brain ventricular system, including the choroid plexuses. This macrophage infiltration was accompanied by severe tissue damage, including ventriculitis, choroid plexitis, and meningoencephalitis. Specifically, choroid plexus endothelium-derived EBOV infection led to viral persistence in the macaque brain ventricular system. This resulted in apoptosis of ependymal cells, which constitute the blood–cerebrospinal fluid barrier of the choroid plexuses. Fatal brain-confined recrudescence of EBOV infection manifested as severe inflammation, local pathology, and widespread infection of the ventricular system and adjacent neuropil in some of the mAb-treated macaque survivors. This study highlights organ-specific EBOV persistence and fatal recrudescent disease in rhesus macaque survivors after therapeutic treatment and has implications for the long-term follow-up of human survivors of EVD.

25 July 2019 in JCI Insight
Verified
Journal Article
Open access
PDF file
JLJun Liu
Jun Liu
KCKayla M. Coffin
Kayla M. Coffin
SJSara C. Johnston
Sara C. Johnston
ABApril M. Babka
April M. Babka
TBTodd M. Bell
Todd M. Bell
XZXiankun Zeng
Xiankun Zeng
Nipah virus (NiV) is an emerging zoonotic paramyxovirus that causes highly lethal henipavirus encephalitis in humans. Survivors develop various neurologic sequelae, including late-onset and relapsing encephalitis, several months up to several years following initial infection. However, the underlying pathology and disease mechanisms of persistent neurologic complications remain unknown. Here, we demonstrate persistent NiV infection in the brains of grivets that survived experimental exposure to NiV. Encephalitis affected the entire brains, with the majority of NiV detected in the neurons and microglia of the brainstems, cerebral cortices, and cerebella. We identified the vascular endothelium in the brain as an initial target of NiV infection during the acute phase of disease, indicating a primary path of entry for NiV into the brain. Notably, we were unable to detect NiV anywhere else except the brains in the examined survivors. Our findings indicate that late-onset and relapsing encephalitis of NiV in human survivors may be due to viral persistence in the brain and shed light on the pathogenesis of chronic henipavirus encephalitis.

10 May 2022 in Viruses
Verified
Journal Article
Open access
PDF file
SBSandra Bixler
Sandra Bixler
CSChristopher P. Stefan
Christopher P. Stefan
AJAlexandra Jay
Alexandra Jay
FRFranco D. Rossi
Franco D. Rossi
KRKeersten M. Ricks
Keersten M. Ricks
LPLouise Pitt
Louise Pitt
The emergence of SARS-CoV-2 and the subsequent pandemic has highlighted the need for animal models that faithfully replicate the salient features of COVID-19 disease in humans. These models are necessary for the rapid selection, testing, and evaluation of potential medical countermeasures. Here, we performed a direct comparison of two distinct routes of SARS-CoV-2 exposure—combined intratracheal/intranasal and small particle aerosol—in two nonhuman primate species, rhesus and cynomolgus macaques. While all four experimental groups displayed very few outward clinical signs, evidence of mild to moderate respiratory disease was present on radiographs and at necropsy. Cynomolgus macaques exposed via the aerosol route also developed the most consistent fever responses and had the most severe respiratory disease and pathology. This study demonstrates that while all four models produced suitable representations of mild COVID-like illness, aerosol exposure of cynomolgus macaques to SARS-CoV-2 produced the most severe disease, which may provide additional clinical endpoints for evaluating therapeutics and vaccines.